Noxopharm Ltd has released a press release.
Noxopharm to expedite Veyonda Clinical Program
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- FNN interview with Nox Chief Medical Officer on Interim Data
- Veyonda and Radiotherapy Delivers Clinical Benefits
- Principal Investigator Discusses LuPIN-1 Study
- NOX Receives $3.26M Federal Govt R&D Rebate
- DARRT-1 study advancing on basis of positive clinical data
Later from Noxopharm
- KZA: Kazia sells stake in Noxopharm
- Veyonda Chemotherapy Enhancement Program to be Expanded
- Idronoxil Confirmed as New Immuno-Oncology Drug
- Veyonda and Immuno-Oncology Effect Explained
- DARRT Treatment Has Lasting Disease Control at Six Months
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm